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General Information: 
All the reagents and solvents used in this study, were purchased from Sigma Aldrich, Thermo 
Fischer Scientific and TCI chemicals respectively. Open capillary was used to measure all the 
melting points. IR spectrum of the solid sample was recorded in the range 500 to 3500 cm
-1
 in an 
FT-IR spectrometer in KBr cell. Bruker 600 MHz spectrometer was used to record all 
1
H and 
13
C 
NMR spectra. EI mass spectral analysis was done using JEOL The Mstation JMS-700 
instrument. All the UV & Fluorescence data were collected using Jasco & Cary Eclipse 
spectrophotometer respectively. Bruker Kappa Apex II X-raycrystallography machine was used 
to solve the crystal structure. Singlet (s), doublet (d), triplet (t) & multiplet (m) were designated 
as 
1
H NMR multiplicity patterns. Silica gel (60-120 mesh) and (100-200 mesh) were used for 
column chromatographic separations. 
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Synthetic Procedures: 
 Procedure for the synthesis of 2-(2-iodophenyl)imidazo[1,2-a]pyridine, 3: 
To a solution of 1 (1gm, 1.0 eq.) and 2 (2.61gm, 1.0 eq.) in 1,2-DCB (4ml), was added 
Cu(OAc)2.H2O (212 mg, 0.1 eq.), ZnI2 (340 mg, 0.1 eq.) & 1,10-Phenanthroline (192 mg, 0.1 
eq.) and heated in a round bottom flask under ambient air for 24 hours. The reaction was 
monitored through TLC until the starting material consumed completely. After that, the reaction 
mixture was diluted with dichloromethane and filtered through celite bed. The organic layer was 
then concentrated under reduced pressure and subjected to column chromatography (silica gel 
60-120 mesh size, ethyl acetate: pet ether) for further purification to get the desired compound, 3 
in 85% yield as a yellow solid. 
Procedure for the synthesis of 2-([1,1'-biphenyl]-2-yl)imidazo[1,2-a]pyridine, 4: 
To a solution of Compound  3 in dry DMF (3 ml), different Phenyl boronic acids were used for 
Suzuki cross coupling reaction in presence of Pd(PPh3)4  and K2CO3 at 130 
o
C in a sealed tube 
under N2 atmosphere. The reaction was monitored through TLC until complete consumption of 
the starting material. After that, the reaction mixture was diluted with ethyl acetate and passed 
through celite bed and then washed with cold water (2×10 ml) and brine (1×10 ml). The organic 
layer was then filtered, dried over Na2SO4 and concentrated under reduced pressure to get crude 
solid, which was subjected to column chromatography (silica gel 100-200 mesh size, ethyl 
acetate: pet ether) for further purification to get the desired compound, 4 in good yield, . 
Procedure for the synthesis of phenanthro[9',10':4,5]imidazo[1,2-a]pyridine, 5: 
To a solution of Compound  4 (150 mg, 1.0 eq.) in dry DMF (3ml), was added Pd(OAc)2 (6 mg, 
0.05 eq.) as catalyst, Ag2CO3 (7 mg, 0.05 eq.) as co-oxidant and PivOH (8 l, 0.15 eq.) as 
additive at 140 
o
C in a sealed tube under ambient pressure of molecular oxygen for final 
dehydrogenative cyclisation. After completion of the reaction, monitored by TLC, the reaction 
mixture was diluted with ethyl acetate, filtered through celite bed and then washed with cold 
water (4× 10 ml) and brine (2×10 ml). The organic layer was then collected and dried over 
Na2SO4. After that the organic extract was evaporated under reduced pressure to get crude solid. 
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It was then subjected to column chromatography (silica gel 100-200 mesh size, ethyl acetate: pet 
ether) for further purification to get the desired compound, 5 in 52-85% yield. 
 
phenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5a) 
 
Pale yellow solid; yield 85%; m.p. 98-99
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.19 (d, J = 
6.0 Hz, 1H), 8.94 (dd, J = 6.0, 6.0 Hz, 1H), 8.89 (d, J = 6.0 Hz, 1H), 8.76 (d, J = 6.0 Hz, 1H), 
8.55 (d, J = 6.0 Hz, 1H), 7.99 (d, J = 6.0 Hz, 1H), 7.74 – 7.80 (m, 3H), 7.68 (t, J = 18 Hz, 1H), 
7.48 ((t, J = 18 Hz, 1H), 7.12 (t, J = 6.8 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 
147.54, 138.44, 129.76, 129.63, 128.34, 127.47, 127.33, 127.04, 126.51, 126.13, 124.73, 124.59, 
123.78, 123.67, 123.20, 120.00, 119.74, 118.29, 112.46; Mass: [EI-HRMS] (C19H12N2) calc. 
268.1000 Da, Found: 268.0995Da; FTIR (KBr, max, cm
−1
): 3418.13, 2925.45, 1632.71, 1522.91, 
1421.40, 1357.44, 1269.57, 1129.18, 824.21, 748.38, 530.27 
2-methylphenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5b) 
 
Pale yellow solid; yield 83%; m.p. 141-142
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.21 (d, J = 
6.0 Hz, 1H), 8.91 (d, J = 6.0 Hz, 1H), 8.76 (d, J = 6.0 Hz, 1H), 8.72 (d, J = 6.0 Hz, 1H), 8.31 (s, 
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1H), 8.01 (d, J = 12.0 Hz, 1H), 7.79 – 7.70 (m, 2H), 7.53 – 7.46 (m, 2H), 7.13 (t, J = 12.0 Hz, 
3H), 2.71 (s, 3H); 
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 147.44, 137.21, 129.72, 128.38, 
127.05, 126.99, 126.57, 126.51, 126.28, 126.13, 126.10, 124.97, 124.47, 123.76, 123.31, 122.98, 
119.78, 118.21, 112.41, 22.04; Mass: [EI-HRMS] (C20H14N2) calc. 282.1157 Da, Found: 
282.1166Da; FTIR (KBr, max, cm
−1
): 3427.25, 2924.18, 2856.39, 1622.75, 1455.67, 1361.68, 
1242.51, 810.54, 725.36 
3-methylphenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5c) 
 
Pale yellow solid; yield 81%; m.p. 140-141
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.11 (t, J = 
12.0 Hz, 1H), 8.90 (d, J = 6.0 Hz, 1H), 8.73 (d, J = 6.0 Hz, 1H), 8.65 (s, 1H), 8.38 (t, J = 18.0 
Hz, 1H), 7.98 (d, J = 12.0 Hz, 1H), 7.78 – 7.71 (m, 2H), 7.58 (d, J = 6.0 Hz, 1H), 7.46 (t, J = 
12.0 Hz, 1H), 7.09 (t, J = 12.0 Hz, 1H), 2.67 (s, 3H); 
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 
147.12, 134.41, 129.42, 128.68, 128.48, 127.35, 126.93, 126.89, 126.42, 125.96, 125.08, 124.62, 
123.76, 123.16, 121.27, 119.62, 119.33, 118.12, 112.39, 21.91; Mass: [EI-HRMS] (C20H14N2) 
calc. 282.1157 Da, Found: 282.1150Da; FTIR (KBr, max, cm
−1
): 3420.66, 2922.33, 1631.70, 
1531.35, 1426.16, 1359.92, 1265.92, 1151.49, 764.85, 728.31, 583.18, 533.05 
2-methoxyphenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5d) 
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Pale yellow solid; yield 84%; m.p. 110-111
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.10 (d, J = 
6.0 Hz, 1H), 8.88 (d, J = 6.0 Hz, 1H), 8.78 (d, J = 6.0 Hz, 1H), 8.64 (d, J = 12.0 Hz, 1H), 7.99 (d, 
J = 6.0 Hz, 1H), 7.91 (s, 1H), 7.74 – 7.69 (m, 2H), 7.48 (t, J = 18.0 Hz, 1H), 7.29 (d, J = 6.0 Hz, 
1H), 7.11 (t, J = 12.0 Hz, 1H), 4.08 (s, 3H); 
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 147.57, 
141.57, 129.79, 127.10, 126.48, 126.27, 126.16, 126.09, 125.84, 124.79, 123.77, 122.64, 122.34, 
118.97, 118.22, 112.45, 112.07, 103.76, 55.61; Mass: [EI-HRMS] (C20H14N2O) calc. 298.1106 
Da, Found: 298.1119Da; FTIR (KBr, max, cm
−1
): 3419.82, 2930.69, 1617.08, 1530.07, 1460.03, 
1426.44, 1360.23, 1309.93, 1225.38, 1034.91, 816.40, 730.43 
2-phenylphenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5e) 
 
Light yellow solid; yield 82%; m.p. 228-229
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.25 (d, J 
= 6.0 Hz, 1H), 8.94 (d, J = 6.0 Hz, 2H), 8.78 (d, J = 12.0 Hz, 1H), 8.70 (s, 1H), 8.01 (d, J = 6.0 
Hz, 1H), 7.91 (d, J = 12.0 Hz, 1H), 7.85 (d, J = 12.0 Hz, 2H), 7.82 – 7.74 (m, 2H), 7.60 (t, J = 
12.0 Hz, 2H), 7.51 (t, J = 18.0 Hz, 2H), 7.14 (t, J = 12.0 Hz, 1H); 
13
C NMR (150 MHz,DMSO-
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d6) δ (ppm) 141.50, 141.12, 140.26, 129.49, 129.08, 128.32, 127.79, 127.60, 127.48, 127.14, 
127.04, 122.46, 126.53, 126.18, 125.20, 125.07, 124.13, 124.02, 123.83, 123.25, 119.30, 118.37, 
118.25, 112.59; Mass: [EI-HRMS] (C25H16N2) calc. 344.1313 Da, Found: 344.1320Da; FTIR 
(KBr, max, cm
−1
): 3440.88, 3036.96, 1612.30, 1497.30, 1449.63, 1357.89, 1269.80, 1145.92, 
824.21, 753.39, 723.79, 689.95 
2-ethylphenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5f) 
 
Light yellow solid; yield 80%; m.p. 142-143
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.19 (d, J 
= 12.0 Hz, 1H), 8.91 (d, J = 6.0 Hz, 1H), 8.78 (d, J = 6.0 Hz, 1H), 8.72 (d, J = 6.0 Hz, 1H), 8.31 
(s, 1H), 7.98 (d, J = 12 Hz, 1H), 7.77 – 7.71(m, 2H), 7.53 (d, J = 6.0 Hz, 1H), 7.48 t, J = 18.0 
Hz, 1H), 7.12 (t, J = 18.0 Hz, 1H), 3.00 (q, J = 7.6 Hz, 2H), 1.46 (t, J = 18.0 Hz, 3H); 
13
C NMR 
(150 MHz, DMSO-d6) δ (ppm) 147.47, 143.49, 141.16, 129.71, 127.01, 126.94, 126.63, 126.55, 
126.33, 125.96, 125.05, 124.57, 123.84, 123.71, 123.00, 119.23, 118.60, 118.24, 112.33, 29.34, 
15.87; Mass: [EI-HRMS] (C21H16N2) calc. 296.1313 Da, Found: 296.1317Da; FTIR (KBr, max, 
cm
−1
): 3430.48, 3042.63, 2961.18, 2923.76, 1622.26, 1519.87, 1453.11, 1422.27, 1359.17, 
1242.09, 1150.17, 824.65, 721.61 
phenanthro[9',10':4,5]imidazo[1,2-a]pyridine-2-carbonitrile (5g) 
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Light yellow solid; yield 56%; m.p. 275-276 
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.13 (d, J 
= 12.0 Hz, 1H), 8.97 (d, J = 6.0 Hz, 2H), 8.83 (s, 1H), 8.75 (d, J = 6.0 Hz, 1H), 8.03 (d, J = 12.0 
Hz, 1H), 7.90 – 7.87 (m, 2H), 7.81 (t, J = 12.0 Hz, 1H), 7.58 (t, J = 18.0 Hz, 1H), 7.24 (t, J = 
12.0 Hz, 1H);
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 147.92, 138.48, 132.36, 131.09, 130.46, 
129.31, 129.14, 128.73, 128.36, 127.69, 127.11, 126.27, 124.09, 124.02, 123.82, 120.02, 118.65, 
113.78, 113.31, 111.62; Mass: [EI-MS] (C20H11N3) calc. 293.0953 Da, Found: 293 Da (No 
HRMS due to matrix peak matching); FTIR (KBr, max, cm
−1
): 3439.70, 2925.00, 2855.20, 
2360.99, 2227.19, 1629.55, 1517.10, 1451.47, 1424.55, 1363.11, 1312.44, 1246.50, 828.37, 
734.66 
2-(trifluoromethyl)phenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5h) 
 
Pale yellow solid; yield 52%; m.p. 278-279
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.15 (d, J = 
12.0 Hz, 1H), 8.99 (d, J = 6.0 Hz, 1H), 8.96 (d, J = 6.0 Hz, 1H), 8.78 (d, J = 6.0 Hz, 2H), 8.02 (d, 
J = 12.0 Hz, 1H), 7.90 – 7.84 (m, 2H), 7.80 (t, J = 18.0 Hz, 1H), 7.56 (t, J = 18.0 Hz, 1H), 7.21 
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(t, J = 12.0 Hz, 1H);
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 148.02, 141.93, 130.46, 128.78, 
128.57, 127.75, 127.47, 126.80, 126.33, 125.32, 125.26, 123.97, 123.64, 123.26, 120.62, 118.33, 
118.72, 118.53, 116.61, 113.06, 53.40; Mass: [EI-HRMS] (C20H11F3N2) calc. 336.0874 Da, 
Found: 336.0879 Da; FTIR (KBr, max, cm
−1
): 2924.32, 2853.80,1739.19, 1624.50, 1460.25, 
1324.93, 1292.72, 1262.60, 1166.90, 1110.57, 803.67, 727.58, 594.71 
2-(tert-butyl)phenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5i) 
 
Pale yellow solid; yield 78%; m.p. 154-155
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.17 (d, J = 
6.0 Hz, 1H), 8.91 (d, J = 12.0 Hz, 1H), 8.81 (d, J = 12.0 Hz, 1H), 8.73 (d, J = 6.0 Hz, 1H), 8.52 
(s, 1H), 8.01 (d, J = 6.0 Hz, 1H), 7.77 – 7.71 (m, 3H), 7.48 (t, J = 12.0 Hz, 1H), 7.14 (t, J = 12.0 
Hz, 1H), 1.58 (s, 9H); 
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 150.23, 147.49, 141.12, 129.59, 
127.06, 126.95, 126.70, 126.39, 126.07, 125.93, 124.33, 123.59, 123.02, 122.87, 119.60, 118.33, 
115.79, 114.04, 112.50, 35.16, 31.53;Mass: [EI-HRMS] (C23H20N2) calc. 324.1626 Da, Found: 
324.1629Da; FTIR (KBr, max, cm
−1
): 3438.60, 2954.90, 1619.57, 1453.44, 1449.63, 1357.78, 
1263.57, 1033.54, 816.45, 769.15, 720.20, 484.13 
4-methylphenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5j) 
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Pale yellow solid; yield 81%; m.p. 141-142
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.18 (d, J = 
6.0 Hz, 1H), 8.98 (d, J = 12.0 Hz, 1H), 8.83 (d, J = 6.0 Hz, 1H), 8.45 (d, J = 6.0 Hz, 1H), 7.97 (d, 
J = 6.0 Hz, 1H), 7.77 (t, J = 12.0 Hz, 1H), 7.71 – 7.64 (m, 2H), 7.53 (d, J = 6.0 Hz, 1H), 7.46 (t, 
J = 12.0 Hz, 1H), 7.08 (t, J = 12.0 Hz, 1H), 3.20 (s, 3H); 
13
C NMR (150 MHz, DMSO-d6) δ 
(ppm) 147.89, 141.08, 137.10, 130.67, 129.61, 128.52, 128.38, 128.00, 126.74, 126.54, 126.30, 
125.98, 125.56, 125.11, 123.57, 119.78, 118.31, 117.64, 112.31, 27.82;Mass: [EI-HRMS] 
(C20H14N2) calc. 282.1157 Da, Found: 282.1147 Da; FTIR (KBr, max, cm
−1
): 3425.15, 2924.22, 
2855.37, 1730.24, 1633.32, 1460.45, 1349.80, 1270.21, 1210.90, 1142.06, 798.16, 756.46, 
716.60 
2-chlorophenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5k) 
 
Light yellow solid; yield 75%; m.p. 268-269
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.07 (d, J 
= 6.0 Hz, 1H), 8.90 (d, J = 12.0 Hz, 1H), 8.76 (d, J = 6.0 Hz, 1H), 8.66 (d, J = 6.0 Hz, 1H), 8.43 
(s, 1H), 7.98 (d, J = 12.0 Hz, 1H), 7.80 – 7.73 (m, 2H), 7.60 (d, J = 12.0 Hz, 1H), 7.52 (t, J = 
18.0 Hz, 1H), 7.16 (t, J = 12.0 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 141.89, 
11 
 
133.36, 129.11, 127.71, 127.32, 126.93, 126.89, 126.59, 126.54, 126.33, 125.98, 124.91, 124.83, 
124.57, 123.87, 123.10, 119.22, 118.38, 112.78;Mass: [EI-HRMS] (C19H11N2Cl) calc. 302.0611 
Da, Found: 302.0605 Da; FTIR (KBr, max, cm
−1
): 3429.05, 3058.42, 2926.08, 1603.46, 1522.62, 
1424.07, 1357.37, 1298.30, 1099.04, 811.52, 759.65, 720.36 
2-methoxy-3-methylphenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5l) 
 
Pale yellow solid; yield 72%; m.p. 137-138
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 8.85 (t, J = 
12.0 Hz, 2H), 8.58 (d, J = 6.0 Hz, 1H), 8.48 (s, 1H), 7.93 (d, J = 12.0 Hz, 1H), 7.70 – 7.67 (m, 
2H), 7.54 (s, 1H), 7.41 (t, J = 12.0 Hz, 1H), 7.01 (t, J = 12.0 Hz, 1H), 4.03 (s, 3H), 2.46 (s, 3H); 
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 157.42, 147.09, 140.62, 129.43, 129.80, 126.25, 
126.14, 125.92, 125.76, 125.63, 124.96, 123.65, 122.60, 121.75, 119.20, 118.09, 112.22, 99.39, 
55.38, 16.89; Mass: [EI-HRMS] (C21H16N2O) calc. 312.1263 Da, Found: 312.1269 Da; FTIR 
(KBr, max, cm
−1
): 3420.75, 3061.67, 29.20.71, 2849.71, 1622.66, 1526.41, 1461.86, 1426.10, 
1360.93, 1248.58, 1203.10, 1167.81, 1040.93, 800.50, 763.82, 716.70 
11-methylphenanthro[9',10':4,5]imidazo[1,2-a]pyridine (5m) 
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Light yellow solid; yield 83%; m.p. 194-195
o
C; 
1
H NMR (600 MHz, Chloroform-d) δ 9.02 (d, J 
= 12.0 Hz, 1H), 8.90 (d, J = 6.0 Hz, 1H), 8.87 (d, J = 6.0 Hz, 1H), 8.75 (d, J = 6.0 Hz, 1H), 8.48 
(d, J = 12.0 Hz, 1H), 7.79 – 7.71 (m, 4H), 7.65 (t, J = 12.0 Hz, 1H), 6.91 (d, J = 6.0 Hz, 1H), 
2.55 (s, 3H); 
13
C NMR (150 MHz, DMSO-d6) δ (ppm) 148.13, 141.11, 137.27, 129.49, 128.04, 
127.33, 127.21, 127.11, 126.77, 125.63, 124.51, 124.37, 123.71, 123.69, 123.15, 119.55, 118.95, 
116.63, 115.01, 21.51; Mass: [EI-HRMS] (C20H14N2) calc. 282.1157 Da, Found: 282.1148Da; 
FTIR (KBr, max, cm
−1
): 3429.61, 3043.01, 2917.02, 2851.79, 1644.78, 1606.29, 1521.54, 
1490.58, 1447.65, 1418.66, 1361.11, 1298.89, 1237.02, 1206.81, 1166.47, 1037.98, 846.26, 
755.08, 715.71, 603.95 
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1
H NMR spectrum of compound 5a in CDCl3 
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C NMR spectrum of compound 5a in CDCl3 
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H NMR spectrum of compound 5b in CDCl3 
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H NMR spectrum of compound 5c in CDCl3 
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1
H NMR spectrum of compound 5d in CDCl3 
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C NMR spectrum of compound 5d in CDCl3 
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1
H NMR spectrum of compound 5e in CDCl3 
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H NMR spectrum of compound 5f in CDCl3 
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C NMR spectrum of compound 5f in CDCl3 
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H NMR spectrum of compound 5g in CDCl3 
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1
H NMR spectrum of compound 5h in CDCl3 
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1
H NMR spectrum of compound 5i in CDCl3 
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H NMR spectrum of compound 5j in CDCl3 
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C NMR spectrum of compound 5j in CDCl3 
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H NMR spectrum of compound 5k in CDCl3 
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1
H NMR spectrum of compound 5l in CDCl3 
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C NMR spectrum of compound 5l in CDCl3 
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1
H NMR spectrum of compound 5m in CDCl3 
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C NMR spectrum of compound 5m in CDCl3 
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UV/Vis & Fluorescence study 
 
For UV/Vis & Fluorescence study, 5M of each compound solution was prepared in CH2Cl2 and 
then the respective spectrophotometers were used to record all the data. 
 
 
Entry Compound max (nm) em (nm) ФF 
1 5d 223 413 0.61 
2 5e 224 416 0.44 
3 5f 226 410 0.47 
4 5j 228 414 0.35 
5 5k 227 405 0.22 
 
Table S1: Fluorescence quantum efficiency of the compounds (5 M in CH2Cl2) determined 
by Phenanthrene (ФF = 0.125, ex = 255 nm) as a standard. 
 
 
 
 
 
Figure S1: Solid state images of compound 5e in (A) Normal light & (B) Under UV (365 nm)  
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Biological Study 
 
Cell culture 
Human hepatocellular liver carcinoma cells (HepG2) cell line (NCCS, Pune, India), were grown 
in DMEM supplemented with 10% FBS and antibiotics (penicillin-100 µg/ml; streptomycin-50 
µg/ml). Cells were cultured at 37 ºC in 95% air, 5% CO2 incubator.   
 
Cell Cytotoxicity Assay 
Cytotoxicity for the compounds 5d and 5e was determined using MTT assay. HepG2 cells (1 × 
10
5
 cells/well) were cultured in a 96-well plate at incubated at 37 °C, and were exposed to 
varying concentrations of the two compounds (1, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 μM) 
for 24hrs. After the incubation, 10 μl of MTT solution [5 mg/ml, dissolved in 1X phosphate-
buffered saline (PBS)] was added to each well of a 96-well culture plate, and then incubated at 
37 
o
C for 4 hrs. Media were decanted from wells and 150µl of DMSO was added in each well 
and absorbance was measured at 550nm (EMax Precision MicroPlate Reader, Molecular 
Devices, USA). All experiments were performed in triplicate and the relative cell viability (%) 
was expressed as a percentage relative to the untreated control cells. 
Cell Imaging Study 
HepG2 Cells were culture in 35 x 10 mm culture dish on coverslip for 24h at 37 
o
C. The cells 
were allowed to incubate with 10μm solutions of the compounds 5d and 5e, prepared by 
dissolving it to the organic solvent DMSO. To characterize the intracellular fluorescence activity 
of the two compounds,  HepG2 cells were preincubated with 10 µM ,20µM and 40µM
 
of 5d and 
5e for 60 min at 37 
o
C followed by washing twice with 1X PBS. Fluorescence images of HepG2 
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cells were taken by a fluorescence microscope (Leica DM3000, Germany) with an objective lens 
of 40X magnification. 
 
Figure S2: Cell viability curve for compound 5d and 5e 
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Cell imaging picture with compound 5d: 
 
 Figure S3: (A) Bright field & (B) Fluorescence images of HepG2 cells at 40X magnification 
after preincubation with 10 µM to 20µM to 40µM
 
of  5d for 60 min at 37 
o
C followed by 
washing twice with 1X PBS. 
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Cell imaging picture with compound 5e: 
 
Figure S4: (A) Bright field & (B) Fluorescence images of HepG2 cells at 40X magnification 
after preincubation with 10 µM to 20µM to 40µM
 
of  5e for 60 min at 37 
o
C followed by 
washing twice with 1X PBS. 
